Related Experiment Videos
[Clinical studies with a mezlocillin-oxacillin combination in a children's intensive care ward]
Insights
Optocillin, a mezlocillin and oxacillin combination, demonstrated good tolerance and effectiveness in treating severe pediatric infections. This antibiotic combination shows promise for use in pediatric intensive care settings.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Antibiotic Therapy
Context:
- Severely infected children, including premature infants, require effective and well-tolerated antimicrobial treatments.
- Assessing novel antibiotic combinations is crucial for managing complex pediatric infections.
Purpose:
- To evaluate the therapeutic efficacy and safety of Optocillin (mezlocillin-oxacillin combination) in pediatric patients with severe infections.
- To determine the tolerance profile of this antibiotic combination in a pediatric intensive care setting.
Summary:
- Optocillin, a combination of mezlocillin and oxacillin, was administered to 25 severely infected children, including 10 premature infants.
- Therapeutic success was observed in 21 of 22 survivors, with good tolerance reported and no definite severe side effects.
- The study suggests Optocillin is an effective broad-spectrum antibiotic with good tolerability for pediatric intensive care.
Impact:
- Provides evidence for the clinical utility of mezlocillin-oxacillin combination in treating severe pediatric infections.
- Highlights the favorable safety profile of Optocillin in a vulnerable pediatric population.
- Informs clinical decision-making regarding antibiotic selection for pediatric intensive care units.
Abstract:
25 severely infected children, including 10 premature babies weighing less than 2000 g, were treated with Optocillin, Bay 1-1330 a combination of 6-((R)-2-[methylsulfonyl-2-oxo-imidazolidine-1-carboxamido]-2-phenyl-acetamido)-penicillanic acid sodium salt (mezlocillin, Baypen) and 5-methyl-3-phenyl-4-isoxazolypenicillin (oxacillin, Stapenor). Three children died, but probably only one of them of an (uncomfirmed) infection. Very good therapeutic results were obtained in 10 of the 22 survivors, good results in 11 children, and there was one therapeutic failure. In 9 cases an aminoglycoside antibiotic (mostly amikacin) was given in addition during the critical phase of the disease. The daily dose ranged between 120 and 270 mg/kg bodyweight, corresponding to 80-180 mg mezlocillin and 40-90 mg oxacillin/kg bodyweight. The duration of treatment was between 5 and 38 days. Severe side effects definitely produced by the compound were not observed; a rise in the liver-specific laboratory values of one patient was not definitely attributable to medication. According to this study, the combination mezlocillin-oxacillin can be rated as an antibiotic well effective against a broad range of pathogens and marked by a good tolerance especially in the children's intensive care ward.